A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer-Reference-Cited by-同舟云学术

A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer

Published:2003-07 Issue:4 Volume:56 Page:1073-1078
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Takamiya Robert,Weinberg Vivian,Young C.Dale,Sandler Howard,McLaughlin Peter,Roach Mack

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference14 articles.

1. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy;Russell;J Urol,1991

2. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate;Zagars;Int J Radiat Oncol Biol Phys,1993

3. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer;Lee;J Urol,1996

4. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer;Ritter;J Clin Oncol,1992

5. The role of PSA in the radiotherapy of prostate cancer;Roach;Oncology,1996

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiation dose-response (a Bayesian model) in the radiotherapy of the localized prostatic adenocarcinoma: the reliability of PSA slope changes as a response surrogate endpoint;PeerJ;2019-07-01

2. Dynamic contrast enhanced MRI monitoring of primary proton and carbon ion irradiation of prostate cancer using a novel hypofractionated raster scan technique;Radiotherapy and Oncology;2016-08

3. High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success;Radiotherapy and Oncology;2015-04

4. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir;Radiation Oncology;2014-02-02

5. PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated With Freedom From Prostate-Specific Antigen Failure;International Journal of Radiation Oncology*Biology*Physics;2012-06